Optinose Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutic solutions for patients suffering from sinus and allergy-related conditions
The company's primary product utilizes its proprietary drug delivery technology to administer medications directly to the nasal cavity, aimed at improving the treatment efficacy for various disorders, including chronic rhinosinusitis and allergic rhinitis. Through its commitment to research and development, Optinose strives to enhance patient outcomes and quality of life by delivering effective, non-invasive treatment options.
Paratek will acquire Optniose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19.
